

BIOCRYST PHARMACEUTICALS INC  
Form 8-K  
November 08, 2004

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

## FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: November 8, 2004

### BioCryst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-23186**  
(Commission  
File Number)

**62-1413174**  
(IRS Employer  
Identification #)

**2190 Parkway Lake Drive, Birmingham, Alabama 35244**  
(Address of Principal Executive Office)

**(205) 444-4600**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 

#### Item 8.01 Other Events.

On November 8, 2004, Registrant issued a press release announcing the initiation of the clinical development of BCX-4208 for psoriasis. The press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K.

Neither the filing of any press release as an exhibit to this Current Report on Form 8-K nor the inclusion in such press release of a reference to Registrant's Internet address shall, under any circumstances, be deemed to incorporate the information available at such Internet address into this Current Report on Form 8-K. The information available at Registrant's Internet address is not part of this Current Report on Form 8-K or any other report filed by Registrant with the Securities and Exchange Commission.

#### Item 9.01 Exhibits.

Exhibit No.	Description
99.1	Press release dated November 8, 2004 entitled BioCryst Pharmaceuticals Initiates Clinical Development of BCX-4208 for Psoriasis .

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 8, 2004

BioCryst Pharmaceuticals, Inc.

By:                   /s/ Michael A. Darwin

Michael A. Darwin  
Chief Financial Officer and  
Chief Accounting Officer

---

**EXHIBIT INDEX**

<b>Item</b>	<b>Description</b>
99.1	Press release dated November 8, 2004 entitled BioCryst Pharmaceuticals Initiates Clinical Development of BCX-4208 for Psoriasis .

---